Elizabeth Evans, NP
Adult Health · Albuquerque, NMNPI 1750341426
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (50.9%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 27 manufacturers reported payments, led by GSK at 51.0% of the total. Reporting peaked in 2022 at $3,611 and has fallen 81.7% since, to $660 in 2025. Among adult health clinicians in NM with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 119 payments — averaging $76.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$5K
- Nxstage Medical, Inc.$717
- Boehringer Ingelheim$480
- AstraZeneca$478
- Novo Nordisk$469
- Amgen$283
- plus $2K from 21 others
What the payments were for
- Consulting fees$4,35048%
- Travel & lodging$1261%
- Food & beverage$4,64751%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 6 | $4,649 |
| Nxstage Medical, Inc. | 9 | $717 |
| Boehringer Ingelheim | 17 | $480 |
| AstraZeneca(2 entities) | 13 | $478 |
| Novo Nordisk | 15 | $469 |
| Amgen(2 entities) | 5 | $283 |
| Lilly USA, LLC | 9 | $269 |
| Corcept Therapeutics | 4 | $220 |
| Sanofi-aventis U.S. LLC | 6 | $197 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 2 | $168 |
| Abbott | 1 | $154 |
| Vifor Pharma, Inc. | 4 | $143 |
| Bayer | 3 | $141 |
| Akebia Therapeutics Inc | 2 | $135 |
| Dexcom, Inc. | 5 | $114 |
| Mozarc Medical US LLC | 1 | $94 |
| Aurinia Pharma U.S., Inc. | 2 | $84 |
| Baxter Healthcare | 1 | $78 |
| Fresenius USA Marketing, Inc. | 3 | $51 |
| Otsuka America Pharmaceutical, Inc. | 2 | $38 |
| Mallinckrodt Hospital Products Inc. | 2 | $35 |
| AbbVie | 1 | $28 |
| IBSA Pharma Inc. | 2 | $26 |
| Merck | 1 | $23 |
| Daiichi Sankyo Inc. | 1 | $21 |
| Calliditas Therapeutics US Inc. | 1 | $19 |
| Xeris Pharmaceuticals, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NXSTAGE SYSTEM ONE$317
- LIBERTY SELECT CYCLER$208
- FreeStyle Libre$154
- Korlym$133
- Ozempic$124
- JARDIANCE$121
- LOKELMA$120
- Tavneos$115
- FARXIGA$113
- Vafseo$111
- Kerendia$109
- PUREFLOW SL$109
- RYBELSUS$104
How this compares
$9,123 in reported general payments places this provider in the 95th percentile of 52 adult health providers in New Mexico.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VelphoroSucroferric Oxyhydroxide | 67 | $168,264 |
| AuryxiaFerric Citrate | 31 | $51,140 |
| Lanthanum Carbonate | 51 | $44,914 |
| Sevelamer Carbonate | 98 | $20,339 |
| TrulicityDulaglutide | 19 | $19,281 |
| EliquisApixaban | 15 | $16,812 |
| OzempicSemaglutide | 13 | $15,245 |
| LokelmaSodium Zirconium Cyclosilicate | 22 | $5,788 |
| Furosemide | 126 | $1,270 |
| Calcium Acetate | 13 | $1,028 |
| Bumetanide | 18 | $901 |
| Carvedilol | 59 | $731 |
| Metoprolol Succinate | 25 | $693 |
| Amlodipine Besylate | 54 | $665 |
| Losartan Potassium | 49 | $649 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Fresenius USA Marketing, Inc.Velphoro | $51 | $168,26467 claims |
| Akebia Therapeutics IncAuryxia | $135 | $51,14031 claims |
| Lilly USA, LLCTrulicity | $269 | $19,28119 claims |
| Novo NordiskOzempic | $469 | $15,24513 claims |
| AstraZenecaLokelma | $478 | $5,78822 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 52 adult health providers in New Mexico.
Other adult health in Albuquerque
- Leslie DorkAlbuquerque$7K
- Stephanie MahootyAlbuquerque$6K
- Debra NarcisseAlbuquerque$5K
- Sara RogersAlbuquerque$2K
- Theresa CastlemainAlbuquerque$2K
- Melissa TorresAlbuquerque$2K
- Deborah AnayaAlbuquerque$1K
- Clyde SanchezAlbuquerque$1K
- Sheila MisraAlbuquerque$1K
- Michele HeadAlbuquerque$992
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.